Listed by the USPTO as SPENCER, ANDREA LYNNE MORRIS
Tech Center 1600 • Art Units: 1631 1647
This examiner grants 20% of resolved cases
SPENCER, ANDREA LYNNE MORRIS works in tech center 1600 and art unit 1631. The profile records 10 resolved cases, an allowance rate of 20.0%, and a median of 1435 days to allowance. The very small case volume limits predictive confidence, but the observed allowance rate indicates a demanding record and the median timing points to extended prosecution.
The interview lift is 37.5%, suggesting that interviews may have practical value when addressing examination issues, subject to the limited record. The leading companies are The Trustees of the University of Pennsylvania, University of Massachusetts, and Intellia Therapeutics Inc. The listed firms are Clark+Elbing LLP, HOWSON & HOWSON LLP, and Apex Attorneys at Law, LLP.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17639962 | ADENO-ASSOCIATED VIRUS VECTOR PLATFORM FOR DELIVERY OF KH902 (CONBERCEPT) AND USES THEREOF | Final Rejection | University of Massachusetts |
| 18031470 | POLOXAMERS FOR CELL CULTURE | Final Rejection | MERCK PATENT GMBH |
| 17407606 | NONVIRAL GENERATION OF GENOME EDITED CHIMERIC ANTIGEN RECEPTOR T CELLS | Final Rejection | Wisconsin Alumni Research Foundation |
| 17772106 | BASE-EDITING SYSTEMS | Final Rejection | Inari Agriculture Technology, Inc. |
| 18340593 | VIRAL VECTOR-PRODUCING CELLS HAVING IMPROVED ABILITY TO PRODUCE VECTOR, METHOD FOR PRODUCING SAME AND METHOD FOR SELECTING SAME | Non-Final OA | AGC INC. |
| 18194691 | ANKYRIN-RICH BTB/POZ DOMAIN-CONTAINING PROTEIN-2 (ABTB2) FOR SUPPRESSING PANCREATIC CANCER GROWTH | Final Rejection | The Curators of the University of Missouri |
| 18040648 | NOVEL AAV CAPSIDS AND COMPOSITIONS CONTAINING SAME | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17997110 | COMPOSITIONS AND METHODS FOR REDUCING NUCLEASE EXPRESSION AND OFF-TARGET ACTIVITY USING A PROMOTER WITH LOW TRANSCRIPTIONAL ACTIVITY | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17278679 | EDITING OF HAEMOGLOBIN GENES | Final Rejection | Oxford University Innovation Limited |
| 17426993 | ADENO-ASSOCIATED VIRUS DELIVERY OF CLN6 POLYNUCLEOTIDE | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17920088 | HIGHLY-NETWORKED CORONAVIRUS IMMUNOGEN COMPOSITION | Non-Final OA | Massachusetts Eye and Ear Infirmary |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy20.0% of resolved applications examined by Andrea Lynne Morris Spencer were allowed (10 resolved cases), compared with 28.4% across Art Unit 1631 over the last five years.
This examiner's interview lift is +37.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Andrea Lynne Morris Spencer took 1,435 days on average from filing to allowance.
Andrea Lynne Morris Spencer examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
